NCT04381819

Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19

Status unknown Last updated 11 May 2020

What this trial tests

trial testing SARS-CoV-2 PCR in SARS Virus in 1,000 participants. Status unknown.

Timeline

2 March 2020

Primary endpoint
28 February 2022

31 December 2023

Quick facts

Lead sponsor	Oslo University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	2 March 2020
Primary completion	28 February 2022
Estimated completion	31 December 2023
Sites	7 locations across Norway

Drugs / interventions tested

• SARS-CoV-2 PCR

Conditions studied

• SARS Virus — all drugs for SARS Virus →
• Severe Acute Respiratory Syndrome — all drugs for Severe Acute Respiratory Syndrome →

Sponsor

Oslo University Hospital

Who can join

18 and older, any sex, with SARS Virus or Severe Acute Respiratory Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oslo University Hospital has initiated an observational study on hospitalised patients with confirmed COVID-19, the infection caused by Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
   Holter JC, Pischke SE, de Boer E, Lind A, et al · · 2020 · cited 312× · PMID 32943538 · DOI 10.1073/pnas.2010540117
2. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure.
   Ueland T, Holter JC, Holten AR, Müller KE, et al · · 2020 · cited 123× · PMID 32603675 · DOI 10.1016/j.jinf.2020.06.061
3. Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19.
   Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, et al · · 2020 · cited 73× · PMID 33303843 · DOI 10.1038/s41598-020-78710-7
4. Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement.
   Hoel H, Heggelund L, Reikvam DH, Stiksrud B, et al · · 2021 · cited 73× · PMID 32976665 · DOI 10.1111/joim.13178
5. Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19.
   Aamodt AH, Høgestøl EA, Popperud TH, Holter JC, et al · · 2021 · cited 53× · PMID 33743046 · DOI 10.1007/s00415-021-10517-6
6. Elevated plasma sTIM-3 levels in patients with severe COVID-19.
   Ueland T, Heggelund L, Lind A, Holten AR, et al · · 2021 · cited 37× · PMID 32971109 · DOI 10.1016/j.jaci.2020.09.007
7. Gut microbiota composition during hospitalization is associated with 60-day mortality after severe COVID-19.
   Trøseid M, Holter JC, Holm K, Vestad B, et al · · 2023 · cited 30× · PMID 36814280 · DOI 10.1186/s13054-023-04356-2
8. Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns.
   Christensen EE, Jørgensen MJ, Nore KG, Dahl TB, et al · · 2021 · cited 21× · PMID 34080738 · DOI 10.1111/joim.13310